옵션 체인은 다양한 행사가격과 만기일에 대한 Paramount Glb의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Paramount Glb에 대한 시장 심리를 평가합니다..

Paramount Glb (NASDAQ:PARAA) 주식, 옵션 체인

Paramount Glb

Paramount Global

Paramount Global operates in three global business segments: TV media, filmed entertainment, and direct to consumer. The TV media business includes television production studios and various broadcast and cable networks, including CBS, 15 owned CBS affiliates, Paramount, Nickelodeon, MTV, BET, and VH1. Filmed entertainment consists multiple film studios, most importantly Paramount Pictures. The film studios produce and distribute movies that they license to movie theaters and other media outlets. Direct to consumer includes the Paramount+, Pluto TV, and BET+ streaming services. Much of the content on Paramount's streaming platforms is created by the production studios housed within the firm's other two business segments.

Paramount

Entertainment

News

Markets

Tech

PARA

PARAA

파라마운트 글로벌(NASDAQ:PARA)(NASDAQ:PARAA)은 2025년 1분기 주요 콘텐츠 출시와 슈퍼볼의 영향이 사라지면서 파라마운트 플러스(Paramount+) 가입자 증가세가 둔화될 것으로 예상하고 있다.

&#39;파라마운트 플러스&#39; 가입자 성장, 2025년 1분기에 둔화 예상...슈퍼볼 효과 이어지지 않는 이유는?

10 Trending Netflix Shows You Need To Check Out This Week

Education

AAPL

AMZN

CMCSA

FOXA

GOOG

GOOGL

NFLX

ROKU

넷플릭스(NASDAQ:NFLX)의 주식이 수요일에 사상 최고가를 기록했다. 이는 분기 실적 보고서가 애널리스트 예상치를 상회했고 가입자 수가 사상 최고로 증가한 결과이다. 주가 상승으로 인해, 넷플릭스는 이제 네 개의 미국 방송 네트워크를 소유한 미디어 회사들과 여러 다른 스트리밍 회사들을 합친 것보다 더 높은 가치를 지니게 되었다.

넷플릭스는 디즈니, 파라마운트, 컴캐스트 및 폭스를 합친 것보다 더 큰 가치 기록

Director,Chair,movie,Clapper,In,Studio.concept,For,Film,Industry.3d,Rendering

Media

로스앤젤레스의 퍼시픽 팰리세이드 지역과 다른 지역에서 발생한 화재가 엔터테인먼트 산업에 빠르게 영향을 미치고 있다. 현지 소방서가 이 재난을 진압하고 추가 피해를 최소화하기 위해 노력하는 동안 여러 TV 프로그램이 제작을 중단했다.

LA 화재로 &#39;폴아웃&#39; 등의 TV 프로그램 제작 중단; 영화 시사회 취소, 영화평론가상 연기

'Sundar Pichai And Tim Cook Talked About Gemini Deal, Pichai Says' - The Information

Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) launched a <a href="https://www.benzinga.com/topic/e-commerce">new rapid-delivery feature</a> on its Taobao shopping platform on Wednesday to compete in China's fast-growing on-demand delivery market against rivals like JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) and Meituan. 
The new &#8220;instant commerce&#8221; tab appeared on Taobao's homepage in dozens of Chinese cities. It allows users to order a wide variety of products, including food, apparel, and footwear, and receive their purchases in under an hour.
Read Next: <a href="https://www.benzinga.com/news/legal/25/04/45056354/alexandria-ocasio-cortez-askshow-much-did-majorie-taylor-greene-make-when-she-bought-the-dip?utm_source=articleShare">Alexandria Ocasio-Cortez Asks,&#8217;How Much Did Marjorie Taylor Greene Make When She Bought The Dip?&#8217;</a>
According to a Wall Street Journal <a href="https://www.wsj.com/tech/alibaba-rolls-out-instant-commerce-feature-as-china-delivery-battle-heats-up-3f6e665a">report</a>, Alibaba confirmed the rollout of the rapid-delivery service, which leverages its food delivery arm Ele.me to fulfill orders, and plans to expand the service throughout China by May 6.
The rapid-delivery service is a significant step in Alibaba's strategy to integrate its online marketplaces with its delivery network and comes as competition heats up in China's on-demand delivery sector.&nbsp;
JD.com, for example, is aggressively expanding its own rapid delivery services and plans to hire tens of thousands of full-time riders. Meituan remains the dominant player with about two-thirds of China's food delivery market, according to the South China Morning Post.&nbsp;
BABA Stock Price Action:&nbsp; Shares of Alibaba Group were down slightly at $118.85 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/social-media/25/04/45076599/sell-in-may-and-go-away-only-in-bear-markets-one-expert-says?utm_source=articleShare">&#8216;Sell In May And Go Away?&#8217; Only In Bear Markets, One Expert Says&nbsp;</a></li>
</ul>
Photo: Shutterstock

Global

Movers

BABA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Alibaba Launches 'Instant Commerce' Rapid-Delivery To Compete With Chinese E-Commerce Rivals

WIIM

Gildan Activewear shares are trading higher after the company reported better-than-expected Q1 financial results.

Wells Fargo analyst Ike Boruchow maintains Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) with a Equal-Weight and lowers the price target from $210 to $115.

Price Target

Analyst Ratings

DECK

Wells Fargo Maintains Equal-Weight on Deckers Outdoor, Lowers Price Target to $115

CHEF

The Chefs' Warehouse shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance.

BioNexus Gene Lab Corp. (NASDAQ:<a href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>), a biotechnology company specializing in precision diagnostics and specialty chemical solutions, today announced that it has received official notification from The Nasdaq Stock Market LLC ("Nasdaq") confirming the Company has regained full compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of $1.00 per share.

BGLC

BioNexus Gene Lab Corp. Regains Nasdaq Compliance

FOUR

Shift4 Payments shares are trading lower after the company announced it launched a public offering consisting of 7.5 million series A mandatory convertible preferred stock. Additionally, UBS cut its price target on the stock from $138 to $125.

U.S. stocks were lower, with the Dow Jones index falling around 200 points on Wednesday.
Shares of Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose sharply during Wednesday's session after the company reported better-than-expected third-quarter adjusted EPS results and issued fourth-quarter adjusted EPS guidance <a href="https://www.benzinga.com/quote/WDC/earnings">above estimates.</a>
Western Digital reported quarterly earnings of $1.36 per share which beat the analyst consensus estimate of $1.13 per share. The company reported quarterly sales of $2.29 billion which missed the analyst consensus estimate of $2.36 billion.
Additionally, the company declared a quarterly dividend of $0.10 per share.
Western Digital jumped 6.5% to $43.24 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) jumped 59% to $50.14.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 18.8% to $55.99 after the company reported better-than-expected first-quarter financial results and raised its FY25 guidance.</li>
<li>Concord Medical Services Holdings Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) gained 16.6% to $9.15.</li>
<li>Cantor Equity Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEP#NASDAQ">CEP</a>) jumped 15.5% to $37.81.</li>
<li>Silicon Motion Technology Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) jumped 14.6% to $51.78 after the company reported better-than-expected quarterly financial results.</li>
<li>Global Industrial Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) gained 14.1% to $25.31 after the company reported better-than-expected quarterly financial results.</li>
<li>Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) jumped 10.7% to $255.26 following upbeat quarterly earnings.</li>
<li>Qorvo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QRVO#NASDAQ">QRVO</a>) gained 10.6% to $69.33 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter guidance with its midpoint above estimates.</li>
<li>Seagate Technology Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) gained 9.2% to $89.21 following third-quarter results.</li>
<li>Trane Technologies plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) gained 7.6% to $380.43 after the company reported better-than-expected first-quarter financial results and raised its FY25 GAAP EPS and sales guidance above estimates.</li>
<li>XPO, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) jumped 7.5% to $104.78 after the company reported better-than-expected quarterly EPS results.</li>
<li>The Chefs&#8217; Warehouse, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>) gained 7% to $57.00 following upbeat earnings.</li>
<li>Gildan Activewear Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) rose 6.2% to $45.56 following strong quarterly earnings.</li>
<li>PPG Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPG#NYSE">PPG</a>) gained 3.7% to $107.68 after the company reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/45064976/top-3-industrials-stocks-which-could-rescue-your-portfolio-in-q2">Top 3 Industrials Stocks Which Could Rescue Your Portfolio In Q2</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Trading Ideas

QRVO

SIMO

WING

Western Digital Posts Better-Than-Expected Earnings, Joins Wingstop, Qorvo, Seagate And Other Big Stocks Moving Higher On Wednesday

Wells Fargo analyst Ike Boruchow maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Overweight and lowers the price target from $325 to $300.

BURL

Wells Fargo Maintains Overweight on Burlington Stores, Lowers Price Target to $300

ENVA

Enova International shares are trading lower. The company reported Q1 financial results.

Wells Fargo analyst Ike Boruchow maintains Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) with a Overweight and lowers the price target from $48 to $40.

BBWI

Wells Fargo Maintains Overweight on Bath & Body Works, Lowers Price Target to $40

Federal Signal shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 adjusted EPS guidance.

Yuanbao Shares Halted On Circuit Breaker To The Downside

ETSY

Etsy shares are trading lower following a Q1 adjusted EPS miss.

Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) agreed to acquire Regulus Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGLS#NASDAQ">RGLS</a>) on Wednesday for an initial payment of $7.00 per share in <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">cash or $0.8 billion</a>.
The upfront cash portion of the consideration represents a premium of 274% to Regulus&#8217; 60-day volume-weighted average stock price and 108% to Regulus&#8217; closing <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n45095629/regulus-therapeutics-enters-into-agreement-to-be-acquired-by-novartis-ag" rel="noreferrer noopener">price on&nbsp;April 29, 2025</a>.
Regulus is a clinical-stage biopharmaceutical company developing microRNA therapeutics for severe renal disease and autosomal dominant polycystic kidney disease (ADPKD).
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/45075714/novartis-q1-earnings-beat-street-view-ceo-confident-to-deliver-upgraded-2025-guidance" rel="noreferrer noopener">Novartis Q1 Earnings Beat Street View, CEO &#8216;Confident&#8217; In Delivering Upgraded Guidance</a>
The lead asset for ADPKD, farabursen, is a novel, next-generation oligonucleotide targeting miR-17 that recently completed a Phase 1b multiple-ascending dose clinical trial.
In addition, Regulus shareholders will receive a contingent value right (CVR) providing for payment of&nbsp;$7.00&nbsp;per share, contingent upon the achievement of a milestone regarding the regulatory approval of Regulus&#8217; lead product candidate, farabursen.
If the milestone is achieved, total consideration, including the CVR, would be approximately&nbsp;$1.7 billion.
The transaction is expected to close in the second half of 2025. Regulus will continue to operate as a separate and independent company.
In March, Regulus Therapeutics released topline results from all patients in the fourth cohort in its Phase&nbsp;1b&nbsp;MAD study of farabursen <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44519887/regulus-therapeutics-stock-shoots-higher-after-positive-results-from-investigational-drug-for-rare-type-of-kidney-disease" rel="noreferrer noopener">(RGLS8429) for ADPKD</a>.
Cohort 4 data highlights:
<ul>
<li>Increases in urinary PC1 and PC2 levels were similar to cohort 3 and reached a similar level of statistical significance compared to placebo (PC1 p=0.026; PC2 p=0.014).</li>
<li>The mean htTKV growth rate over 4 months was 0.05%, while placebo subjects in the trial experienced a mean growth rate of 2.58%.</li>
<li>Changes in htTKV were highly correlated with changes in renal cyst volume, suggesting farabursen directly impacts disease progression by limiting abnormal cyst growth.</li>
</ul>
Novartis strengthened its kidney disease portfolio after the U.S. Food and Drug Administration (FDA) granted accelerated approval for&nbsp;Vanrafia (atrasentan) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44631273/novartis-secures-third-fda-approval-for-its-kidney-disease-portfolio-in-one-year" rel="noreferrer noopener">rapid disease progression</a>.
This is Novartis' third U.S. approval for its kidney disease portfolio in the last year. Fabhalta&nbsp;was granted FDA approval in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44544720/fda-oks-novartis-prostate-cancer-treatment-triples-eligible-patient-pool" rel="noreferrer noopener">C3 glomerulopathy in&nbsp;March 2025</a>&nbsp;and accelerated approval in&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40254535/fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease" rel="noreferrer noopener">IgAN in&nbsp;August 2024</a>.
Price Action: RGLS stock is up 132.9% at $7.85 during the premarket session at the last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/45084149/trade-desk-wins-analyst-conviction-on-streaming-growth-over-amazon-competition" target="_blank" rel="noreferrer noopener">Analyst Says Trade Desk Can Shake Off Challenges, Ride Streaming&#8217;s Next Big Wav</a></li>
</ul>
Photo: Shutterstock

Biotech

Large Cap

Health Care

General

RGLS

Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million

Kadant shares are trading lower after the company reported worse-than-expected Q1 sales results, issued Q2 guidance below estimates, and cut its FY25 guidance.

Above Food Ingredients Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVE#NASDAQ">ABVE</a>) ("Above Food") today announced that it has reached agreement on essential terms and conditions for its proposed merger with Palm Global Technologies Ltd. ("Palm Global"), advancing the transformative acquisition first announced on February 6, 2025.
The executive management team of Above Food has completed its comprehensive review of the proposed merger terms and structure, expressing strong support for this transformative combination. The Company's Board of Directors has received the management team's endorsement and is advancing the necessary corporate and regulatory approvals to facilitate the completion of definitive documentation.
The Above Food executive management team travelled to the Emirates this week to conclude final diligence. Additionally, our leadership team attended a number of groundbreaking milestone events that further demonstrated the success that Palm Global is achieving on its global initiatives.

ABVE

Above Food Ingredients Reaches Key Agreement Terms For Proposed Merger With Palm Global Technologies

Wells Fargo analyst Ike Boruchow maintains Amer Sports (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AS#NYSE">AS</a>) with a Equal-Weight and lowers the price target from $28 to $24.

Wells Fargo Maintains Equal-Weight on Amer Sports, Lowers Price Target to $24

Newell Brands shares are trading lower after the company issued Q2 adjusted EPS guidance below estimates.

Wells Fargo analyst Ike Boruchow maintains Academy Sports (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) with a Equal-Weight and lowers the price target from $43 to $38.

Wells Fargo Maintains Equal-Weight on Academy Sports, Lowers Price Target to $38

Press Releases

Paramount+ and EverPass Media Announce Multi-Year Distribution Agreement to Bring CBS Sports' UEFA Champions League to Commercial Businesses

NICKELODEON ANNOUNCES ALL-NEW ANIMATED SERIES AVATAR: SEVEN HAVENS SET IN THE WORLD OF AVATAR: THE LAST AIRBENDER

NICKELODEON UNVEILS BRAND-NEW ANIMATED PRESCHOOL SERIES SUPER DUPER BUNNY LEAGUE

Dividends

PARAMOUNT GLOBAL DECLARES QUARTERLY CASH DIVIDEND

Earnings

PARAMOUNT GLOBAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 EARNINGS RESULTS

NORD, Paramount Pictures Join Forces to Raise Awareness of Rare Disease

NICKELODEON AND SPIN MASTER ENTERTAINMENT PICK UP PAW PATROL® AND RUBBLE & CREW™ FOR NEW EPISODE ORDERS

NICKELODEON ANNOUNCES ALL-NEW ANIMATED SERIES WYLDE PAK, MOVING IN THIS SUMMER

Paramount Global to Report First Quarter 2025 Financial Results on May 8, 2025

Delaware Court Finds Credible Basis in Gabelli Asset Management Inc. (GAMI) Pursuing Operation Fishbowl

Comments

Paramount Glb

Paramount Glb (PARAA) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌